Fri, Dec 26, 2014, 5:32 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • kennydong kennydong Jul 15, 2014 12:02 PM Flag

    1-for-10 Reverse

    Bad news!

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Shallow assessment (emphasis on 1st 3 letters)

    • You are correct...will open tomorrow at $11.80 and within the next few months they will need/want/have to raise cash......the usual reasons, corporate expenditures etc.. where you will experience your first of many dilutions. Still got stock in this bottomless pit? Too late if you have.

    • ctbradley11@att.net ctbradley11 Jul 15, 2014 3:36 PM Flag

      Agree !! This does no one any good - selling today.

      • 1 Reply to ctbradley11
      • Does this even have a chance to occur in 2014?
        EPIRUS is a Boston-based, privately held company, backed by Montreux Equity Partners, TPG
        Biotech, and 5AM Ventures. EPIRUS is developing a broad pipeline of biosimilars for commercialization in major emerging markets. Our first product is BOW015, a biosimilar to Remicade®. BOW015 has successfully completed P1 and P3 clinical trials. We anticipate first market approval and launch in 2014.

        Sentiment: Hold

    • "1:10 Reverse Stock Split will be effective before trading opens on July 16
      EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian #$%$
      BOSTON--(BUSINESS WIRE)-- EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today the completion of a merger with Zalicus Inc. (Zalicus, NASDAQ:ZLCS).

      The combined company, which has been renamed EPIRUS Biopharmaceuticals, Inc., will focus on the business of EPIRUS and operate under the leadership of the EPIRUS management team, with Amit Munshi serving as the president and chief executive officer. The merger and name change became effective today. Beginning on July 16, 2014, EPIRUS will trade on NASDAQ under the symbol EPRS.

      EPIRUS also announced a reverse stock split, in which, following the merger, every ten (10) shares of the company's common stock will be combined and reclassified into one (1) share of the company's common stock. The reverse stock split will be completed before NASDAQ opens for trading on July 16, 2014."

 
ZLCS
1.180.00(0.00%)Jul 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.